Mi az ára Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. (VKTX) ára $34.45

Mi a Viking Therapeutics, Inc. (VKTX piaci tőkésítése)

Viking Therapeutics, Inc. piaci tőkésítése (VKTX) $4.02B

Viking Therapeutics, Inc. (VKTX) Osztalékhozam

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Év	Osztalékhozam	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Osztalékhozam

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Osztalékhozam	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Vállalat

Osztalékhozam

Ország